VijayKKasturiMD

PubMed

• Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
  Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Bria...> ;The Oncologist. 2024 Mar 4
• Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
  Pedro C Barata, Alexander Chehrazi-Raffle, Kimberly D Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K Pal> ;The Oncologist. 2023 Oct 3
• 1 citations
  A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).
  Sharmeen Mahmood, Daneng Li, Arielle Lee, Julie Rowe, Muhammed Beg, Vijay Kasturi, Renuka Iyer, Thomas Abrams, Farshid Dayyani> ;Future Oncology. 2022 Dec 1
• 1 citations
  Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
  Luis Meza, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Sumanta K Pal, Brian Rini> ;The Oncologist. 2023 Mar 17
• 2 citations
  Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
  Zeynep B Zengin, Sumanta K Pal, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Brian Rini> ;Clinical Genitourinary Cancer. 2022 Dec 1
• 1 citations
  Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as f...
  Thomas E. Hutson, Frank X Liu, Christopher Dieyi, Ruth Kim, Stan Krulewicz, Vijay Kasturi, Abhijeet Bhanegaonkar> ;Journal of Managed Care & Specialty Pharmacy. 2021 Jun 24
• Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy
  Abhijeet Bhanegaonkar, Shivani Pandya, Ying Zheng, Ruth Kim, Stan Krulewicz, Vijay Kasturi, H. Phatak> ;Advances in Therapy. 2021 Apr 17
• 9 citations
  Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
  Charles Lance Cowey, Frank X Liu, Ruth Kim, Marley Boyd, Nicole Fulcher, Stan Krulewicz, Vijay Kasturi, Abhijeet Bhanegaonkar> ;Future Oncology. 2021 Mar 12
• 13 citations
  Efficacy and immune-related adverse event associations in avelumab-treated patients.
  Karen Kelly, Juliane Manitz, Manish R. Patel, Sandra P. D'Angelo, Andrea B. Apolo, Arun Rajan, Vijay Kasturi, Isabell Speit, Marcis Bajars, John Warth, James L. Gulley> ;Journal for Immunotherapy of Cancer. 2020 Nov 1
• 43 citations
  Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
  John Walker, Céleste Lebbé, Giovanni Grignani, Paul Nathan, Luc Dirix, Eyal Fenig, Paolo A. Ascierto, Shahneen Sandhu, Rodrigo Ramella Munhoz, Elena Benincasa, Sarah F...> ;Journal for Immunotherapy of Cancer. 2020 Apr 1
• 69 citations
  Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
  Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun Wook ...> ;Journal for Immunotherapy of Cancer. 2019 Jan 16
• 102 citations
  Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
  Christophe Le Tourneau, Christopher J. Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebrec...> ;Journal for Immunotherapy of Cancer. 2018 Oct 22
• Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III...
  Breathnach, O. S., Kasturi, V., Kaye, F., Herscher, L., Georgiadis, M. S., Edison, M., Schuler, B. S., Pizzella, P., Steinberg, S. M., O'Neil, K., Johnson, B. E.> ;Am J Clin Oncol. 2002 Jun
• Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
  Breathnach, O. S., Georgiadis, M. S., Schuler, B. S., Pizzella, P., Llorens, V., Kasturi, V., Steinberg, S. M., O'Neil, K., Takimoto, C. H., Johnson, B. E.> ;Clin Cancer Res. 2000 Jul
• Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
  Kasturi, V. K., Dearing, M. P., Piscitelli, S. C., Russell, E. K., Sladek, G. G., O'Neil, K., Turner, G. A., Morton, T. L., Christian, M. C., Johnson, B. E., Kelley, M...> ;Clin Cancer Res. 1998 Sep
• Join now to see all